Zynga Launches Harry Potter: Puzzles & Spells Worldwide
23.9.2020 13:00:00 EEST | Business Wire | Press release
Today, Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced that its magical Match-3 mobile game Harry Potter: Puzzles & Spells has officially launched and begun rolling out to territories worldwide. Officially licensed from Warner Bros. Games and published under the Portkey Games label, the game is available for free download on Android and iOS devices, as well as on Amazon Kindle and Facebook.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005144/en/
Zynga Launches Harry Potter: Puzzles & Spells Worldwide (Photo: Business Wire)
“When the Harry Potter series first came to theatres, it was one of those rare moments when everyone was reading the same book, talking about the same film and coming together around a shared experience,” said Yaron Leyvand, Senior Vice President of Games at Zynga. “Harry Potter: Puzzles & Spells honours fans' connection to the series with a mobile game infused with the standout moments and delightful Wizarding World flourishes that have captivated a global following. The feedback from soft-launch has been outstanding, and we can’t wait for fans around the world to play.”
“Mobile games have never been more popular or more important to people than they are right now. People are playing games for entertainment, relaxation, and as an accessible source of comfort and connection,” said Bernard Kim, President of Publishing at Zynga. “With Harry Potter: Puzzles & Spells, fans will immerse themselves in the magic, puzzles, and wonder of the series and create Clubs to collaborate and connect with others fans of Wizarding World.”
In Harry Potter: Puzzles & Spells, players enter a Match-3 adventure brimming with the spells, humour, colour and characters of the Harry Potter series. Featuring the soundtrack and voiceover recordings from the original Harry Potter films, fans follow an authentic, mobile retelling of Harry’s journey through the Wizarding World. Earning spells and special boosts as they advance, players solve Match-3 puzzles populated with hopping Chocolate Frogs, fluttering Winged Keys, battling wizard chess pieces, and other unexpected obstacles and objects. Between colourful puzzles, players will be treated to iconic moments from the narrative, such as Harry’s journey on the Hogwarts Express, Hagrid’s magical creatures and Hermione casting the Wingardium Leviosa spell.
Building their magical aptitude, players earn spells, powerups, and experience points as they progress through the game to level up their skills and in-game personas. Players can also earn powerful rewards by completing Daily Events that reference a multitude of moments from the Harry Potter series. In the spirit of the camaraderie and friendly competition of Hogwarts, players can join or form clubs with other fans to socialise, collaborate on puzzle strategies, share lives and vie for prizes in exclusive Club Events.
For the next seven days, players who download the game for their Android or iOS device will instantly receive the Welcome Bundle, containing in-game gold, extra lives and special Quidditch Goggles to customize their avatars.
Harry Potter: Puzzles & Spells is playable for iOS and Android devices worldwide, as well as on Amazon Kindle and Facebook. For more details, visit the game’s website at www.harrypotterpuzzlesandspells.com. For more information and to connect with other fans, follow us on Facebook, Instagram and Twitter.
For supporting still and video assets, visit: http://bit.ly/HPPuzzlesSpells_WWL
About Zynga
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. To date, more than one billion people have played Zynga’s franchises including CSR Racing TM, Empires & Puzzles TM, Merge Dragons! TM, Merge Magic! TM, Toon Blast™, Toy Blast™, Words With Friends TM and Zynga Poker TM. Zynga’s games are available in more than 150 countries and are playable across social platforms and mobile devices worldwide. Founded in 2007, the company is headquartered in San Francisco with locations in the U.S., Canada, U.K., Ireland, India, Turkey and Finland. For more information, visit www.zynga.com or follow Zynga on Twitter, Instagram, Facebook or the Zynga blog.
About Warner Bros. Games
Warner Bros. Games, a division of Warner Bros. Home Entertainment, Inc., is a premier worldwide publisher, developer, licensor and distributor of entertainment content for the interactive space across all platforms, including console, handheld, mobile and PC-based gaming for both internal and third-party game titles. Additional information about Warner Bros. Games can be found at https://www.wbgames.com/.
About Portkey Games
Portkey Games, from Warner Bros. Games, is the games label dedicated to creating new Wizarding World mobile and videogame experiences that place the player at the center of their own adventure, inspired by J.K. Rowling’s original stories. Portkey Games offers players the opportunity to make their own narrative choices and engage with the Wizarding World setting to create new and unique experiences. The label was created to bring gamers and fans new gaming experiences that allow them to delve into the magic of the Wizarding World in immersive ways where they can define their own Wizarding World story.
Forward Looking Statements
This press release contains forward-looking statements relating to, among other things, the name, gameplay details, game features, and a limited-time promotion in Harry Potter: Puzzles & Spells. Forward-looking statements often include words such as “outlook,” “projected,” “planned,” “intends,” “will,” “anticipate,” “believe,” “target,” “expect,” and statements in the future tense are generally forward-looking. The achievement or success of the matters covered by such forward-looking statements involves significant risks, uncertainties and assumptions. Undue reliance should not be placed on such forward-looking statements, which are based on information available to us on the date hereof. We assume no obligation to update such statements. More information about these risks, uncertainties, and assumptions is or will be described in greater detail in our public filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained by visiting our Investor Relations website at http://investor.zynga.com or the SEC’s website at www.sec.gov.
WIZARDING WORLD, HARRY POTTER Publishing Rights © J.K. Rowling. HARRY POTTER: PUZZLES & SPELLS, PORTKEY GAMES, WIZARDING WORLD and HARRY POTTER characters, names and related indicia © and ™ Warner Bros. Entertainment Inc. ™ Zynga Inc. All Rights Reserved.
WB SHIELD: ™ & © Warner Bros. Entertainment Inc. (s20)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200923005144/en/
Contact information
Dana Whitney
dwhitney@zynga.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 202620.10.2026 16:02:00 EEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27 in Madrid, Spain. The studies span Guardant's cancer portfolio, including tissue-free minimal residual disease (MRD) surveillance, treatment response, and resistance research. Significant studies were conducted independently by industry collaborators, academic institutions, and Guardant’s public-private partners using the company’s technologies and/or real-world data, underscoring the wide adoption of its platform across the research community. “At ESMO, we will showcase how InfinityAI is advancing our portfolio, strengthening the clinic
First Cessna Citation CJ4 Gen3 Advances Toward Entry Into Service as First Production Unit Rolls out of the Factory20.10.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, recently celebrated the rollout of the first production unit of the Cessna Citation CJ4 Gen3, an important milestone as the aircraft advances toward entry into service. The rollout represents Textron Aviation's continued investment in the light jet lineup, bringing Garmin G3000 PRIME avionics, Garmin Emergency Autoland and other customer-driven enhancements to the proven Citation CJ4 platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020982419/en/ First Cessna Citation CJ4 Gen3 advances toward entry into service as first production unit rolls out of the factory. (Photo credit: Textron Aviation) “This rollout is a visible result of the care, precision and teamwork that move an aircraft from design intent to a production-ready airplane,” said Eric Cardinali, senior vice president, Manufacturing Operations. “For our manufacturing teams, it represents the discipl
ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 15:00:00 EEST | Press release
ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehensive foundation that captures the relationships between processes, people, systems, risks and controls. Built on a comprehensive Digital Twin of the Organization that connects how work is designed with the execution data that sits around it, ARIS provides this critical layer of Process Context from more than 30 years of enterprise knowledge and experience, something new entrants to the space are struggling to replicate. The importan
Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 15:00:00 EEST | Press release
Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i
Debiopharm Highlights Clinical Momentum Across DDR Portfolio at ESMO 2026, Advancing WEE1-Based Therapies in Ovarian and Uterine Cancers and Glioblastoma20.10.2026 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced their upcoming Phase 1/Phase 2 clinical updates at the European Society for Medical Oncology (ESMO) Congress (Madrid, Spain, 23-27 October). During the event, Debiopharm will highlight clinical updates on its pipeline targeting the DNA Damage Response (DDR), featuring single-agent data on zedoresertib (Debio 0123) as well as rational combination strategies, with both temozolomide in glioblastoma and with lunresertib (Debio2513) in solid tumors. Debiopharm’s planned activities at ESMO 2026 include: Rapid Oral Presentation (Debio 0123-GBM-105 / NCT05765812): Presenting dose escalation data evaluating zedoresertib in combination with temozolomide in patients with recurrent or progressive glioblastoma. Poster Presentation (Debio 0123-102 / NCT05109975): Presenting Phase 1 expansion data evaluating s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom